Want to see IN:ZIMLAB full AI Analyst Report?

Zim Laboratories Ltd. (ZIMLAB) Price & Analysis

0 Followers

ZIMLAB Stock Chart & Stats

₹71.11

-₹1.76(-1.66%)

At close: Jan 08 4:00 PM EST

₹71.11

-₹1.76(-1.66%)

Day’s Range― - ―

52-Week Range₹59.72 - ₹133.95

Previous CloseN/A

Volume52.11K

Average Volume (3M)6.28K

Market Cap

₹6.11B

Enterprise Value₹6.83B

Total Cash (Recent Filing)₹278.02M

Total Debt (Recent Filing)₹1.26B

Price to Earnings (P/E)94.9

Beta1.12

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.19

Shares Outstanding53,658,490

10 Day Avg. Volume5,950

30 Day Avg. Volume6,279

Financial Highlights & Ratios

PEG Ratio-0.97

Price to Book (P/B)1.00

Price to Sales (P/S)0.80

P/FCF Ratio-39.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Contract Manufacturing & Product MixZim’s dual model—branded/generic sales plus contract manufacturing—creates durable, diversified revenue streams. Long-term, manufacturing partnerships smooth demand swings, provide stable capacity utilization, and enable scale benefits versus a pure-play single-product approach.

Balance Sheet SupportRising equity and moderate leverage provide financial flexibility to fund capex, R&D, or absorb shocks without excessive interest burden. A stronger equity base supports strategic investments and reduces refinancing risk over the medium term.

Positive Operating Cash FlowConsistent positive operating cash flow indicates the core business generates cash from operations. That underlying cash conversion supports working-capital needs and can fund operations or selective investments even while free cash flow fluctuates.

Bears Say

Negative Free Cash FlowReturn to negative free cash flow signals the company is not consistently self-funding discretionary investment. Persistent negative FCF forces reliance on external finance, reduces strategic optionality, and heightens vulnerability if margins or revenues deteriorate.

Weakening ProfitabilityA sharp drop in net income and operating profit points to margin pressure and declining earnings quality. If structural (pricing, cost inflation, or mix shifts), sustained weaker profitability will constrain reinvestment, ROE, and capacity to compete long term.

Inconsistent Revenue GrowthIrregular top-line performance reduces predictability and undermines the ability to achieve scale economies. Continued inconsistency suggests product portfolio or market positioning weaknesses that could limit sustainable margin recovery and long-run growth.

Zim Laboratories Ltd. News

Zim Laboratories Schedules One-on-One Meet With Tata Asset Management

Zim Laboratories Ltd. ( ($IN:ZIMLAB) ) has issued an update. Zim Laboratories has announced that it will hold...

1M ago

Zim Laboratories to Close Trading Window Ahead of December Quarter Results

Zim Laboratories Ltd. ( ($IN:ZIMLAB) ) just unveiled an update. Zim Laboratories Limited has announced the closure of...

7M ago

ZIMLAB FAQ

What was Zim Laboratories Ltd.’s price range in the past 12 months?

Zim Laboratories Ltd. lowest stock price was ₹59.72 and its highest was ₹133.95 in the past 12 months.

What is Zim Laboratories Ltd.’s market cap?

Zim Laboratories Ltd.’s market cap is ₹6.11B.

When is Zim Laboratories Ltd.’s upcoming earnings report date?

Zim Laboratories Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 5 days.

How were Zim Laboratories Ltd.’s earnings last quarter?

Zim Laboratories Ltd. released its earnings results on May 19, 2026. The company reported ₹0.76 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.76.

Is Zim Laboratories Ltd. overvalued?

According to Wall Street analysts Zim Laboratories Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Zim Laboratories Ltd. pay dividends?

Zim Laboratories Ltd. pays a Annually dividend of ₹0.167 which represents an annual dividend yield of N/A. See more information on Zim Laboratories Ltd. dividends here

What is Zim Laboratories Ltd.’s EPS estimate?

Zim Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Zim Laboratories Ltd. have?

Zim Laboratories Ltd. has 53,658,490 shares outstanding.

What happened to Zim Laboratories Ltd.’s price movement after its last earnings report?

Zim Laboratories Ltd. reported an EPS of ₹0.76 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5%.

Which hedge fund is a major shareholder of Zim Laboratories Ltd.?

Currently, no hedge funds are holding shares in IN:ZIMLAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Zim Laboratories Ltd.

Established in 1984 and based in Nagpur, India, ZIM Laboratories Limited is a pharmaceutical company that develops, produces, and supplies both finished drug formulations and pre-formulation ingredients. Operating domestically and internationally, ZIM specializes in providing technology-driven drug delivery solutions and exclusive, non-infringing manufacturing processes for generic pharmaceuticals. These offerings span semi-finished and finished product categories, encompassing forms like granules, pellets, taste-masked powders, suspensions, tablets, capsules, and oral thin films. Their extensive product range caters to various therapeutic areas, including urology, gastroenterology, cardiology, and anticoagulation, alongside antibiotics, anti-infectives, NSAIDs/pain management, and vitamins and supplements.